[42, 43] As in the previous example, the cytokine profile associated with irAEs in this cohort is somewhat unique; elevated levels of IP-10/CXCL10 is associated with the development of irAEs in patients with RCC undergoing combination or monotherapy with ICI. This evidence concerns the gene CXCL10 and renal cell carcinoma.